Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice

Figure 2

Lobeglitazone treatment ameliorates hepatic steatosis in HFD-fed mice. (a) Representative images of livers of NCD-fed mice without treatment (NU), HFD-fed mice without treatment (HU), and HFD-fed mice with lobeglitazone treatment (HL) after 12 weeks of a HFD. (b) Weight of the livers (g/100 g body weight) of NU (black bar), HU (white bar), and HL (black gray bar). (c) Representative images of hematoxylin and eosin staining and Oil Red O staining of liver sections of HFD-fed mice without treatment (HU) and HFD-fed mice with lobeglitazone treatment (HL). (d) Digital image analysis (DIA) quantification of Oil Red O stained sections. a.u., arbitrary units. Data are expressed as means ± SEM. p < 0.05, p < 0.001, and p < 0.0001, NU versus. HU group. ^#p < 0.05, ^##p < 0.001, and ^###p < 0.0001, HU versus. HL group.

(a)

(b)

(c)

(d)